TUDRIQEV Approval in Advanced Melanoma: Mechanism, Clinical Evidence, and Regulatory Outlook

The oncology landscape has witnessed an important development with the FDA’s accelerated approval of tudriqev (vusolimogene oderparepvec-wtpg), previously identified as RP1. Developed by Replimune, the therapy has been approved in combination with Bristol Myers Squibb’s OPDIVO (nivolumab) for adults with unresectable, advanced cutaneous melanoma whose disease has progressed after previous anti-PD-1 treatment. Granted on August 6, 2026, the decision represents a meaningful regulatory achievement for oncolytic virus-based cancer immunotherapy and offers another potential treatment option for patients with advanced melanoma who have limited therapeutic alternatives.

TUDRIQEV Approval Creates a New Option for Advanced Melanoma

The tudriqev approval is especially significant because it addresses a difficult treatment setting in which patients have already experienced disease progression following immune checkpoint inhibition. Although anti-PD-1 therapies have transformed melanoma care, a considerable proportion of patients eventually develop resistance or fail to achieve durable disease control.

In advanced cutaneous melanoma, treatment resistance can substantially restrict subsequent therapeutic choices. The newly approved combination introduces a different strategy by pairing an intratumorally administered oncolytic virus with systemic immune checkpoint blockade. This approach is intended not only to target tumor cells directly but also to stimulate broader antitumor immune responses.

The development is therefore relevant to an increasingly important segment of the melanoma treatment market. More than half of patients with advanced melanoma may experience progression within six months of beginning anti-PD-1 therapy, emphasizing the continuing need for innovative approaches that can potentially restore or enhance immune-mediated tumor control.

TUDRIQEV Mechanism of Action Promotes Local Tumor Destruction and Immune Response

The tudriqev mechanism of action is based on the therapeutic use of a genetically modified herpes simplex virus type 1. The therapy is administered directly into accessible tumors, where the modified virus is designed to replicate preferentially within malignant cells.

Following viral replication, tumor cells can undergo destruction, releasing tumor-associated antigens and inflammatory signals into the surrounding environment. This process may help expose the cancer to the immune system and promote an immune response capable of recognizing malignant cells beyond the lesions that receive direct injection.

The approach differentiates the therapy from conventional systemic treatments that primarily rely on direct pharmacological activity throughout the body. By combining tumor-directed viral activity with immune stimulation, the treatment is designed to potentially convert the tumor into a source of antigens capable of initiating a broader immune response.

This strategy is particularly relevant when paired with nivolumab. As a PD-1 checkpoint inhibitor, nivolumab helps remove an immune-suppressive mechanism that can prevent activated T cells from effectively attacking cancer cells. Together, the two approaches may provide complementary effects, with the viral therapy stimulating tumor immunity while checkpoint inhibition supports immune-cell activity.

TUDRIQEV Clinical Evidence Supports Its Role in Advanced Melanoma

Clinical evidence supporting the regulatory decision came from the Phase I/II IGNYTE study, which evaluated the combination in patients with advanced melanoma. The findings were particularly notable among patients who had measurable disease outside the tumors directly treated with the investigational therapy.